Peritoneal dialysis in developing countries.

K. S. Nayak, M. V. Prabhu, K. A. Sinoj, S. V. Subhramanyam, G. Sridhar

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Peritoneal dialysis (PD) is acknowledged worldwide as a well-accepted form of renal replacement therapy (RRT) for end-stage renal disease (ESRD). Ideally, PD should be the preferred modality of RRT for ESRD in developing countries due to its many inherent advantages. Some of these are cost savings (especially if PD fluids are manufactured locally or in a neighboring country), superior rehabilitation and quality of life (QOL), home-based therapy even in rural settings, avoidance of hospital based treatment and the need for expensive machinery, and freedom from serious infections (hepatitis B and C). However, this is not the ground reality, due to certain preconceived notions of the health care givers and governmental agencies in these countries. With an inexplicable stagnation or decline of PD numbers in the developed world, the future of PD will depend on its popularization in Latin America and in Asia especially countries such as China and India, with a combined population of 2.5 billion and the two fastest growing economies worldwide. A holistic approach to tackle the issues in the developing countries, which may vary from region to region, is critical in popularizing PD and establishing PD as the first-choice RRT for ESRD. At our center, we have been pursuing a 'PD first' policy and promoting PD as the therapy of choice for various situations in the management of renal failure. We use certain novel strategies, which we hope can help PD centers in other developing countries working under similar constraints. The success of a PD program depends on a multitude of factors that are interlinked and inseparable. Each program needs to identify its strengths, special circumstances, and deficiencies, and then to strategize accordingly. Ultimately, teamwork is the 'mantra' for a successful outcome, the patient being central to all endeavors. A belief and a passion for PD are the fountainhead and cornerstone on which to build a quality PD program.

Original languageEnglish
Pages (from-to)270-277
Number of pages8
JournalContributions to Nephrology
Volume163
DOIs
Publication statusPublished - 24-09-2009

Fingerprint

Peritoneal Dialysis
Developing Countries
Renal Replacement Therapy
Chronic Kidney Failure
Latin America
Cost Savings
Ascitic Fluid
Hepatitis C
Hepatitis B
Caregivers
Renal Insufficiency
India
China
Therapeutics
Rehabilitation
Quality of Life

All Science Journal Classification (ASJC) codes

  • Nephrology

Cite this

Nayak, K. S., Prabhu, M. V., Sinoj, K. A., Subhramanyam, S. V., & Sridhar, G. (2009). Peritoneal dialysis in developing countries. Contributions to Nephrology, 163, 270-277. https://doi.org/10.1159/000223810
Nayak, K. S. ; Prabhu, M. V. ; Sinoj, K. A. ; Subhramanyam, S. V. ; Sridhar, G. / Peritoneal dialysis in developing countries. In: Contributions to Nephrology. 2009 ; Vol. 163. pp. 270-277.
@article{0232cfba8f90498fa1fbd32c667392fb,
title = "Peritoneal dialysis in developing countries.",
abstract = "Peritoneal dialysis (PD) is acknowledged worldwide as a well-accepted form of renal replacement therapy (RRT) for end-stage renal disease (ESRD). Ideally, PD should be the preferred modality of RRT for ESRD in developing countries due to its many inherent advantages. Some of these are cost savings (especially if PD fluids are manufactured locally or in a neighboring country), superior rehabilitation and quality of life (QOL), home-based therapy even in rural settings, avoidance of hospital based treatment and the need for expensive machinery, and freedom from serious infections (hepatitis B and C). However, this is not the ground reality, due to certain preconceived notions of the health care givers and governmental agencies in these countries. With an inexplicable stagnation or decline of PD numbers in the developed world, the future of PD will depend on its popularization in Latin America and in Asia especially countries such as China and India, with a combined population of 2.5 billion and the two fastest growing economies worldwide. A holistic approach to tackle the issues in the developing countries, which may vary from region to region, is critical in popularizing PD and establishing PD as the first-choice RRT for ESRD. At our center, we have been pursuing a 'PD first' policy and promoting PD as the therapy of choice for various situations in the management of renal failure. We use certain novel strategies, which we hope can help PD centers in other developing countries working under similar constraints. The success of a PD program depends on a multitude of factors that are interlinked and inseparable. Each program needs to identify its strengths, special circumstances, and deficiencies, and then to strategize accordingly. Ultimately, teamwork is the 'mantra' for a successful outcome, the patient being central to all endeavors. A belief and a passion for PD are the fountainhead and cornerstone on which to build a quality PD program.",
author = "Nayak, {K. S.} and Prabhu, {M. V.} and Sinoj, {K. A.} and Subhramanyam, {S. V.} and G. Sridhar",
year = "2009",
month = "9",
day = "24",
doi = "10.1159/000223810",
language = "English",
volume = "163",
pages = "270--277",
journal = "Contributions to Nephrology",
issn = "0302-5144",
publisher = "S. Karger AG",

}

Nayak, KS, Prabhu, MV, Sinoj, KA, Subhramanyam, SV & Sridhar, G 2009, 'Peritoneal dialysis in developing countries.', Contributions to Nephrology, vol. 163, pp. 270-277. https://doi.org/10.1159/000223810

Peritoneal dialysis in developing countries. / Nayak, K. S.; Prabhu, M. V.; Sinoj, K. A.; Subhramanyam, S. V.; Sridhar, G.

In: Contributions to Nephrology, Vol. 163, 24.09.2009, p. 270-277.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Peritoneal dialysis in developing countries.

AU - Nayak, K. S.

AU - Prabhu, M. V.

AU - Sinoj, K. A.

AU - Subhramanyam, S. V.

AU - Sridhar, G.

PY - 2009/9/24

Y1 - 2009/9/24

N2 - Peritoneal dialysis (PD) is acknowledged worldwide as a well-accepted form of renal replacement therapy (RRT) for end-stage renal disease (ESRD). Ideally, PD should be the preferred modality of RRT for ESRD in developing countries due to its many inherent advantages. Some of these are cost savings (especially if PD fluids are manufactured locally or in a neighboring country), superior rehabilitation and quality of life (QOL), home-based therapy even in rural settings, avoidance of hospital based treatment and the need for expensive machinery, and freedom from serious infections (hepatitis B and C). However, this is not the ground reality, due to certain preconceived notions of the health care givers and governmental agencies in these countries. With an inexplicable stagnation or decline of PD numbers in the developed world, the future of PD will depend on its popularization in Latin America and in Asia especially countries such as China and India, with a combined population of 2.5 billion and the two fastest growing economies worldwide. A holistic approach to tackle the issues in the developing countries, which may vary from region to region, is critical in popularizing PD and establishing PD as the first-choice RRT for ESRD. At our center, we have been pursuing a 'PD first' policy and promoting PD as the therapy of choice for various situations in the management of renal failure. We use certain novel strategies, which we hope can help PD centers in other developing countries working under similar constraints. The success of a PD program depends on a multitude of factors that are interlinked and inseparable. Each program needs to identify its strengths, special circumstances, and deficiencies, and then to strategize accordingly. Ultimately, teamwork is the 'mantra' for a successful outcome, the patient being central to all endeavors. A belief and a passion for PD are the fountainhead and cornerstone on which to build a quality PD program.

AB - Peritoneal dialysis (PD) is acknowledged worldwide as a well-accepted form of renal replacement therapy (RRT) for end-stage renal disease (ESRD). Ideally, PD should be the preferred modality of RRT for ESRD in developing countries due to its many inherent advantages. Some of these are cost savings (especially if PD fluids are manufactured locally or in a neighboring country), superior rehabilitation and quality of life (QOL), home-based therapy even in rural settings, avoidance of hospital based treatment and the need for expensive machinery, and freedom from serious infections (hepatitis B and C). However, this is not the ground reality, due to certain preconceived notions of the health care givers and governmental agencies in these countries. With an inexplicable stagnation or decline of PD numbers in the developed world, the future of PD will depend on its popularization in Latin America and in Asia especially countries such as China and India, with a combined population of 2.5 billion and the two fastest growing economies worldwide. A holistic approach to tackle the issues in the developing countries, which may vary from region to region, is critical in popularizing PD and establishing PD as the first-choice RRT for ESRD. At our center, we have been pursuing a 'PD first' policy and promoting PD as the therapy of choice for various situations in the management of renal failure. We use certain novel strategies, which we hope can help PD centers in other developing countries working under similar constraints. The success of a PD program depends on a multitude of factors that are interlinked and inseparable. Each program needs to identify its strengths, special circumstances, and deficiencies, and then to strategize accordingly. Ultimately, teamwork is the 'mantra' for a successful outcome, the patient being central to all endeavors. A belief and a passion for PD are the fountainhead and cornerstone on which to build a quality PD program.

UR - http://www.scopus.com/inward/record.url?scp=70349263866&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349263866&partnerID=8YFLogxK

U2 - 10.1159/000223810

DO - 10.1159/000223810

M3 - Article

VL - 163

SP - 270

EP - 277

JO - Contributions to Nephrology

JF - Contributions to Nephrology

SN - 0302-5144

ER -